Oncolys BioPharma Inc. is a Tokyo-based bioventure established in Japan in March 2004. Its mission is to contribute to the advancement of medical science in the world through bringing innovation to the existing treatments for cancer and serious infectious diseases, using its virology-based new drug discovery technologies. The company operates in two business segments. Pharmaceutical Business segment is engaged in the research, development, manufacture and marketing of novel drugs. Its major pipeline Telomelysin (OBP-301), an oncolytic adenovirus immunotherapy is in clinical development targeting various types of solid tumors including melanoma , HCC and esophageal cancer. Along with Telomelysin, an anti-HIV drug OBP-601 (Censavudine) and a novel HDAC inhibitor OBP-801 are also under development in the United States. Diagnostics Business segment is engaged in the research, development, manufacture and marketing of CTC (Circulating Tumor Cell) detection adenovirus TelomeScan, as well as the provision of inspection services. Oncolys was listed on the Tokyo Stock Exchange Mothers Market in December 2014 and has a clinical laboratory center in Kobe, Japan and a subsidiary in New Jersey, USA.